3-V Biosciences Finds $20M
Menlo Park-based 3-V Biosciencs, a biopharmaceuticals firm developing therapeutics for the oncology and infectious disease area, said Friday that it has raised $20M in a series C funding. The funding came from existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates. 3-V said the funding will go towards advancing its lead oncology candidate to Phase 1 clinical trials. 3-V Biosciences is led by Merdad Parsey.
posted on Friday, June 21, 2013 (Link to more information)
Related companies:
3-V Biosciences, Inc.
Related stories:
> 3-V Biosciences Finds $20M In Funding
> Xcell Biosciences Finds $12M
> Pacific Biosciences Raises $50M
> Imago Biosciences Sees $26.5M
> Annexon Biosciences Gets $44M
silicontap.com Home